Stem-Cell Monocyte Pyrogen Detection for Pharmaceutical Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pyrogen detection methods, such as the rabbit pyrogen test and Limulus amebocyte lysate assay, are costly, time-consuming, and suffer from variability and limitations in detecting non-endotoxin pyrogens, leading to challenges in ensuring the quality and safety of pharmaceutical compositions.
Innovation Solution
The use of human monocyte or macrophage populations derived from pluripotent stem cells for pyrogen testing, which involves incubating these cells with the composition and determining inflammatory cytokine expression to detect pyrogens, providing a stable and reproducible method for pyrogen detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary monocytes from human donors are used in MAT, then the test can detect pyrogens, but high variability between tests and donors occurs
Solution Approach 1:
The patent uses immortalized monocyte cell lines (such as U937, THP-1, Mono Mac 6) as copies of primary monocytes. These cell lines replicate the pyrogen detection function of primary monocytes while eliminating donor variability, achieving consistent and reproducible test results across multiple experiments without requiring fresh donor samples.
Solution Approach 2:
The patent transforms the biological source parameter from primary human donor monocytes (high variability) to immortalized cell lines (low variability). This parameter change maintains the essential pyrogen detection capability while fundamentally improving test reliability by eliminating inter-donor variation.
2Reliability
If rabbit pyrogen test is used, then pyrogen detection is achieved, but the test is costly and time-consuming
Solution Approach 1:
The patent replaces the in vivo rabbit pyrogen test with an in vitro cell-based assay using immortalized monocyte cell lines. This substitution eliminates the need for live animal testing, significantly reducing cost and time while maintaining pyrogen detection accuracy through measurement of cytokine release (IL-6, TNF-α) as a readout.
Solution Approach 2:
The patent employs disposable immortalized cell lines that can be cultured and used repeatedly without the ethical and logistical constraints of live animal models. These cell lines provide a cost-effective, scalable alternative to rabbit testing, enabling high-throughput pyrogen detection.
3Measurement precision
If LAL assay is used, then endotoxin detection is achieved, but non-endotoxin pyrogens are missed
Solution Approach 1:
The patent employs immortalized monocyte cell lines that respond to multiple types of pyrogens including endotoxins (LPS), non-endotoxin pyrogens (NEPs), and process-related impurities. The monocytes release cytokines in response to diverse pyrogenic stimuli, providing a universal detection platform that surpasses the LAL assay's endotoxin-specific limitation.
Solution Approach 2:
The patent changes the detection mechanism parameter from LAL's specific enzymatic reaction to endotoxin (narrow specificity) to monocyte cytokine release (broad specificity). This parameter change enables detection of multiple pyrogen types by utilizing the monocyte's natural immune response to various pyrogenic substances.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach offers a stable and highly reproducible method for detecting pyrogens, capable of detecting a wide range of pyrogenic substances, including non-endotoxin pyrogens, with low variability and high sensitivity, thus ensuring the quality and safety of pharmaceutical compositions.
Implementation Method 1
determining the quantity of an inflammatory cytokine expressed by the monocytes
Data Source
AI summary
The present invention relates to the field of testing for pyrogens, e.g., endotoxin/LPS, non-endotoxin pyrogen (NEP), process-related impurities or endogenous pyrogens. This is highly relevant, e.g., for quality testing and safety testing of pharmaceutical compositions. The invention provides a method of testing a composition for the presence of at least one pyrogen, comprising (i) incubating a human monocyte or macrophage population derived from pluripotent stem cells in vitro, e.g., a human CD45+/CD11b+/CD14+/CD34−/TRA1-60− monocyte population or CD45+/CD11b+/CD14+/CD34−/TRA1-60−/CD163+ macrophage population derived from pluripotent stem cells with said composition, and (ii) determining a reaction of the monocytes in the population to the presence of the at least one pyrogen, preferably, determining the quantity of an inflammatory cytokine expressed by the monocytes. The invention also provides the use of such monocyte populations for testing a composition for at least one pyrogen, in essence, the use of monocytes derived from pluripotent stem cells for a monocyte activation test (MAT), and kits suitable for this assay. The use of such stem-cell derived monocytes overcomes difficulties raised e.g., by variability of donor cells and allows for test systems that are reproducable and stable in the long term.